As of May 21
| -1.02 / -2.37%|
The 8 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 49.50, with a high estimate of 61.00 and a low estimate of 39.00. The median estimate represents a +17.91% increase from the last price of 41.98.
The current consensus among 9 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.